Background. Little information is available about the kidney's involvement in patients with β-thalassaemia major (TM). In particular, there are no studies reporting the outcome of renal function over time.
Introduction
Many organs and tissues of patients with β-thalassaemia major (TM) are affected by functional abnormalities that can impair their quality of life and even their life expectancy. However, little attention has been paid to the possible impact of the disease and its treatment on the kidney. The majority of available reports were cross-sectional studies and were mainly conducted in children. Markers of proximal tubular damage, such as N-acetyl-D-glucosaminidase, β2 microglobulin, aminoaciduria and/or low-molecularweight proteinuria, were found to be significantly increased in TM children when compared with healthy volunteers [1] [2] [3] [4] [5] [6] . Moreover, some children may present hypercalciuria, hyperphosphaturia, hypermagnesuria, hyperuricuria and/ or glycosuria. These tubular abnormalities have been attributed to iron overload, over aggressive iron removal, and/or the underlying anaemia [7] . Even less information on the changes of estimated glomerular filtration rate (eGFR) is available. Only a few studies were conducted in children with TM, and usually reported that the mean values of creatinine clearance were higher than normal [2, 4, 5, [8] [9] [10] . This glomerular hyperfiltration has been related to the underlying anaemia, which would reduce systemic vascular resistance, leading to a hyperdynamic circulation with subsequent increase in renal plasma flow and eGFR [7] . It is unknown whether these renal abnormalities impair the renal function in the long term.
The aims of the present study were to evaluate the eGFR trend in TM patients referred to the Centre for the Study of Microcytaemia in Cagliari and to assess the determinants of eGFR decline over time.
Materials and methods

Participants
All subjects diagnosed with TM and have been followed for at least 10 years at the Centre for the Study of Microcytaemia between 1996 and 1999 were admitted to the study. All patients received iron chelation with subcutaneous deferoxamine administered over 12 h, seven times a week, at a daily dose of 20-40 mg/kg body weight (BW). In the case of severe iron overload, the dosage of deferoxamine was increased to 60 mg/kg BW. According to a fixed protocol, patients were regularly transfused in order to obtain pretransfusional haemoglobin levels between 9.5 and 10.5 g/dL. To avoid any interference of new iron chelators on renal function, patients who received deferasirox or deferiprone were excluded from the study. Patients who were lost during the study or had an eGFR of <90 mL/min at study entry were also excluded from the study. Each patient accumulated person-years of follow-up from the study entry until kidney damage onset or the end of follow-up (10 years after study entry). During the follow-up, each patient underwent several visits in which demographic and clinical parameters were registered.
This study was approved by the Ethic Independent Committee ASLCagliari, Italy (Protocol N. 175/CE/11 on 19 October 2011)
Outcomes
The primary outcome measure was the variation of eGFR during the follow-up. The Modification of Diet in Renal Disease (MDRD) study simplified equation [11] defined the eGFR. Serum creatinine levels were always measured by the compensated Jaffé method. According to the classification proposed by the National Kidney Foundation [12] , the onset of kidney damage was defined by a first double-checked measure of eGFR <90 mL/min during the follow-up. No important variations in the BW of participants occurred during the study with the exception of a few cases of transient dehydration due to vomit or diarrhoea.
Demographic characteristics and definition of clinical parameters
Several patient's demographic characteristics and clinical parameters were considered in the study as potential determinants of the outcomes under study. Some variables were measured at study entry, namely: age, gender and age at starting chelation. Other variables were assessed throughout the follow-up period and were considered normal according to the following cut-offs (in parentheses): serum creatinine (0.6-1.2 mg/ dL), glycaemia (60-110 mg/dL), uricaemia (2.3-6.0 mg/dL), kalaemia (3.5-5 mEq/L), calcaemia (8.4-10.2 mg/dL), iron intake (<0.3 mg/kg BW), proteinuria (<150 mg/24 h), glycosuria (absent), calciuria (<300 mg/24 h), phosphaturia (<1000 mg/24 h), uricuria (<750 mg/24 h), serum chloride (95-110 mg/dL) and cardiac ejection fraction (>58%) at echocardiography. A pretransfusional haemoglobin between 9.5 and 10.5 g/dL was arbitrarily considered normal for patients with TM. The eGFR was considered as both continuous and dichotomous variables. It was considered to be normal if the value was ≥90 mL/min, while an eGFR of <90 mL/min was considered as kidney damage.
Statistical analysis
Descriptive statistics were conducted for the main characteristics of the patients considered overall, and also separately for those who maintained a normal eGFR and those who showed kidney damage during follow-up as defined by an eGFR of <90 mL/min. The T-test was performed to evaluate whether these two groups were different according to the considered characteristics. To evaluate the effect of the different clinical parameters on the variation of eGFR over time, univariate repeatedmeasures models were applied, taking into account the correlation between eGFR measurement within the same patient. In these models, the eGFR was considered as a continuous response variable, while the different clinical parameters categorized as reported in the previous section were considered as covariates. The variance-covariance matrix selected to account for between measurement correlation was the spatial power law which is specific for unequally spaced data. Univariate Cox's proportional regression models were fitted to estimate hazard ratios (HRs) and 95% confidence interval (CI) for the association between different patient characteristics and the development of kidney function impairment. With the exception of sex, age at study entry and age at the start of chelation, the time-varying clinical parameters were inserted into the model as time-dependent variables.
For all the hypotheses tested, two-tailed P-values <0.05 were considered to be significant. Statistical analysis was performed using SAS Version 9.1 (SAS Institute, Cary, NC, USA).
Results
We obtained data from 115 subjects with TM who were admitted to the Adult Haematology ward, Regional Microcythaemia Hospital of Cagliari, in the period between 1996 and 2009. On admission, the mean age of patients was 28.7 ± 2.4 years (range: 20-50 years). All patients were transfusion-dependent and were treated with iron chelation. From the 115 patients, 34 were not included in the study; 14 of which were previously treated by other hospitals and it was impossible to obtain baseline data, 6 moved to other cities before completing the 10-year follow-up and 14 patients were treated with deferiprone or deferasirox.
Eighty-one patients who met the inclusion criteria were included in the study. Of them, 66 patients maintained normal eGFR values during the follow-up, while 15 patients (18.5%) developed kidney damage. The demographic, haematological and renal parameters of these two patient groups at study entry are reported in Table 1 . The mean basal eGFR levels were significantly lower in patients who developed kidney damage. There were no other differences between the two groups, although more patients who developed kidney damage were carriers of the hepatitis C virus and had haemoglobin levels <9.5 g/dL.
Patients were regularly visited at least two times every week, and more frequently when needed. Five patients in the group that maintained normal eGFR and none among patients with kidney damage developed arterial hypertension during follow-up. In the group of patients who maintained a normal eGFR, the mean eGFR declined from 119.9 mL/min at baseline to 113.6 mL/min after 10 years, i.e. a mean reduction of 6.8 mL/min (P = 0.636). As expected, the decline was stronger in the group of patients who developed kidney damage, from a median eGFR of 98.1 to 78.2 mL/min (−19.9 mL/min; P = 0.004). Figure 1 shows the changes in eGFR over the follow-up for all patients and separately for the two groups of patients.
The repeated-measures models showed that the decline in eGFR over time was significantly higher (P = 0.0068) in patients with baseline phosphaturia >1000 mg/24 h, while eGFR tended to decline more rapidly in patients with baseline uricuria >700 mg/24 h than in patients with uricuria lower than 700 mg/24 h, the difference being at borderline significance (P = 0.0783; Figure 2) . Table 2 reports estimates derived from univariate Cox's proportional hazard models of the effect of selected variables on the risk of kidney damage. Accordingly, abnormal levels of calcaemia were significantly associated with the risk of kidney damage (HR 0.30, 95% CI 0.09-0.97 for calcaemia 8.4-10.2 mg/dL versus HR not estimable for calcaemia <8.4 or >10.2 mg/dL). However, when the time-varying clinical parameters were inserted into the model as time-dependent variables, the risk of kidney damage was more elevated (HR 3.909) in those patients who had wide variations in their haemoglobin levels during the follow-up (data not shown).
No significant association was found between the decline in eGFR and pretransfusion levels of haemoglobin more or less than 9.5 g/dL, age at the start of chelation, compliance to chelation therapy, iron daily intake, splenectomy, renal lithiasis, nephrocalcinosis, uricaemia and cardiac ejection faction. In no case, patients required an overchelation. Most of them received a daily dose of deferoxamine ranging between 20 and 40 mg/kg BW. No association was found between the mean serum ferritin levels and the decline in eGFR. Even when the annual ferritin levels were subdivided into different categories (lower than 500 ng/mL, between 500 and 1000 ng/mL, between 1000 and 1500 ng/mL, between 1500 and 2000 ng/mL, and over 2000 ng/mL), no association was found between any of these levels and decline in eGFR.
Discussion
To the best of our knowledge, this is the first study reporting the changes of eGFR in a cohort of TM adult patients regularly followed-up for 10 years. Looking at the cumulative results, the mean levels of eGFR significantly reduced over time, although remaining in a normal range. However, there was a clear dissociation between 66 patients who maintained a normal eGFR and 15 other patients who developed kidney damage during the followup. In the first group, there was a non-significant decline in eGFR which may be attributable to increasing age. Cross-sectional studies reported a progressive decline in creatinine clearance starting from an age comprised between 20 and 29 years [13, 14] . Lindeman et al. [15] reported an extended longitudinal study of creatinine clearance with repeat measurement for more than 30 years. They found a mean reduction in creatinine clearance of 0.75 mL/min every year, although some patients did not show any decline in renal function. It is difficult to compare their results with our own data, since in the reported studies, the authors measured creatinine clearance in hospitalized patients without renal diseases, while we calculated the eGFR in outpatients according to the MDRD method. Nevertheless, the mean decline in eGFR observed in our patients who maintained a normal eGFR after 10 years of follow-up was similar to that estimated by the data of Lindeman et al. [15] , i.e. 6.8 mL/min versus ∼7.5 mL/min. On the other hand, it is now accepted that there is a small but progressive decline in eGFR starting after 20-30 years of age, and it is reasonable to interpret as a physiological effect of age the decrease in eGFR observed in our patients who maintained a normal eGFR.
However, ∼18% of our patients showed an eGFR of <90 mL/min after 10 years of follow-up. At presentation, the mean eGFR was within a normal range in these patients, but it was significantly lower in comparison with patients who did not have a decline in eGFR. These data suggest that even a mild degree of kidney dysfunction may slowly progress in a subset of patients with TM. We tried to identify the factors associated with this decline in renal function. Patients with a baseline phosphaturia higher than 1000 mg/24 h had a significantly greater decline in eGFR than patients with lower phosphaturia; moreover, a uricuria >700 mg/24 h was at borderline significance. Although one may speculate that the increased phosphaturia at baseline observed in our patients was attributable to the higher levels of eGFR (a mean of 132 9.9 ± 0.5 9.1 ± 2.5 9.7 ± 1.2 1.15 (0.2683) Ejection fraction (%)
62.2 ± 6.6 59.5 ± 9.1 61.8 ± 7.1 1.14 (0.2573) Glycosuria (g/24 h) 1.9 ± 9.6 0.3 ± 1.2 1.6 ± 8. mL/min in patients with higher phosphaturia versus 108 mL/min in patients with phosphaturia <1000 mg/24 h), it is more likely that both hyperphosphaturia and hyperuricuria were caused by persistent tubular damage acquired in their younger age, as it has been reported in many TM children and adolescents with TM [1] [2] [3] [4] [5] [6] . Of note, large variations in haemoglobin levels were also associated with an increased risk of decline in eGFR, showing the importance of maintaining pretransfusional levels of haemoglobin between 9.5 and 10.5 g/dL. Iron overload and anaemia are likely to be the main factors responsible for these tubular abnormalities. Experimental studies have shown that a chronic iron overload state is associated with a marked increase in renal tissue iron content, which may eventually lead to tissue injury [16] . This is also suggested by the good correlation observed between serum ferritin levels and markers of tubular toxicity in some studies [4, 17] and by reversal of tubular defects following iron chelation therapy [17, 18] . On the other hand, high transfusion intensity has been found to be associated with reduced levels of creatinine clearance in patients with TM [19, 20] . Anaemia may also contribute to tubular cell dysfunction. A good correlation between markers of tubular abnormalities and the severity of anaemia has been observed in TM patients [1] . Hypoxia secondary to anaemia may account for these alterations. Moreover, anaemia is associated with oxidative stress [21, 22] , which can contribute to lipid peroxidation and functional abnormalities in tubular cells. We lack information about the treatment received by our patients in their paediatric age. However, it should be noted that the possibility of removing the iron load is relatively recent. Most of the patients participating in this study were born between 1960 and 1980, when guidelines for blood transfusion in TM were not available. As a consequence, our patients suffered from prolonged periods of severe anaemia as they received a blood transfusion only when haemoglobin levels dropped below 6-7 g/dL. Even iron chelation was inadequate. Actually, before 1978, deferoxamine either was not used at all or was administered intramuscularly, with poor absorption. Thus, it is possible to hypothesize that both severe anaemia and iron overload during the childhood may have contributed to cause persistent proximal tubular abnormalities that favoured a mild, slowly progressive kidney dysfunction in the adult age. Our patients were not submitted to kidney biopsy. However, the slow decline in eGFR, the normal or low levels of blood pressure and the absence of relevant proteinuria suggests that these patients had an underlying tubulointerstitial disease [23] . We evaluated the possible role of the covariates in influencing the risk of kidney damage. The Cox proportional hazard regression model showed that the risk of kidney damage was strongly associated with abnormal levels of calcaemia. Our data cannot clarify whether hypocalcaemia was attributable to TM co-morbidities, such as hypoparathyroidism [24] , vitamin D deficiency [25] , intestinal malabsorption [26] or to iron chelation [27] ; nor do we know whether the aetiology of hypercalcaemia was referable to excessive amounts of vitamin D or other causes, including undiscovered parathyroid adenoma [28] . In summary, these data show that adults with TM show a mild decrease in eGFR over time. In most cases, this decline in renal function may be referred to as a result of increasing age. However, almost 20% of the adults with TM show a slow, but progressive decline in eGFR. These patients had a lower baseline eGFR and higher baseline phosphaturia and uricuria, suggesting that tubular abnormalities acquired in childhood may represent a risk factor for kidney function deterioration in the long term. Patients with abnormal levels of calcaemia are also more exposed to the risk of renal function deterioration. However, the significance of this association is still unclear.
Limitations of this study include the retrospective nature and the small sample size. In particular, the small number of associations found in the Cox model may be related to a low statistical power. Further studies in a larger cohort of TM patients are needed to further elucidate the long-term impact of TM on renal function.
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